ArticleChinese clinical oncology2014
Adaptive clinical trial designs in oncology.
Article in Chinese clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- RADVAN: a randomised phase 2 trial of WBRT plus vandetanib for melanoma brain metastases - results and lessons learnt.British journal of cancer · 2016Trial
- A Bayesian Optimal Adaptive Clinical Trial Design for Sequentially Integrated Therapies.Statistics in medicine · 2026Article
- Deciphering double-negative prostate cancer: from aggressive subtype to novel therapeutic paradigms.Cell communication and signaling : CCS · 2026Review
- Harnessing cellular immunotherapy for cholangiocarcinoma: an integrated roadmap for overcoming resistance.Frontiers in immunology · 2026Review
- A narrative review of adaptive Phase I/II clinical trial designs for drug combinations in oncology.Frontiers in oncology · 2026Review
- The Precision Revolution in Hematologic Malignancies: A Decade of Transformative Immunotherapies and Targeted Agents.Journal of clinical medicine · 2025Review
- From Electron Imbalance to Network Collapse: Decoding the Redox Code of Ischemic Stroke for Biomarker-Guided Precision Neuroprotection.International journal of molecular sciences · 2025Review
- The promise of PD1/PDL1 targeted immunotherapy in locally advanced cervical cancer: a game-changer for patients outcome?Frontiers in immunology · 2025Review
- PrimerX: A Bayesian Multistage Cohort Embedded Randomised Trial to Evaluate the Role of Deferred Local Therapy of the Primary Tumour in Combination with Immune Checkpoint Inhibitor-based First-line Therapy in Metastatic Renal Cell Carcinoma Patients.European urology open science · 2024Article
- Comment on "Redefining cancer research for therapeutic breakthroughs".British journal of cancer · 2024Article
- Innovative highlights of clinical drug trial design.Translational research : the journal of laboratory and clinical medicine · 2020Review
- Response adaptive randomization procedures in seamless phase II/III clinical trials.Journal of biopharmaceutical statistics · 2020Article
- Exploiting vulnerabilities in cancer signalling networks to combat targeted therapy resistance.Essays in biochemistry · 2018Review
- Bayesian Adaptive Randomization and Trial Monitoring with Predictive Probability for Time-to-event Endpoint.Statistics in biosciences · 2018Article
- Arguing for Adaptive Clinical Trials in Sepsis.Frontiers in immunology · 2018Review
- Prediction-Oriented Marker Selection (PROMISE): With Application to High-Dimensional Regression.Statistics in biosciences · 2017Article
- Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.Contemporary clinical trials communications · 2017Article
- Phase I cancer clinical trials.Neuro-oncology practice · 2017Review
- PIPELINEs: Creating Comparable Clinical Knowledge Efficiently by Linking Trial Platforms.Clinical pharmacology and therapeutics · 2016Article
- Clinical Trial Adaptation by Matching Evidence in Complementary Patient Sub-groups of Auxiliary Blinding Questionnaire Responses.PloS one · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Adaptive designs have become popular in clinical trial and drug development. Unlike traditional trial designs, adaptive designs use accumulating data to modify the ongoing trial without undermining the integrity and validity of the trial. As a result, adaptive designs provide a flexible and effective way to conduct clinical trials. The designs have potential advantages of improving the study power, reducing sample size and total cost, treating more patients with more effective treatments, identifying efficacious drugs for specific subgroups of patients based on their biomarker profiles, and shortening the time for drug development. In this article, we review adaptive designs commonly used in clinical trials and investigate several aspects of the designs, including the dose-finding scheme, interim analysis, adaptive randomization, biomarker-guided randomization, and seamless designs. For illustration, we provide examples of real trials conducted with adaptive designs. We also discuss practical issues from the perspective of using adaptive designs in oncology trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.